THIRD-GENERATION LAY BARGE WILL SPEED NORTH SEA LINE WORK.

被引：0
|
作者：
Lagers, G.H.G.
Bell, C.R.
机构：
来源：
| 1600年 / 72期
关键词：
Compendex;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
PETROLEUM PIPELINES
引用
收藏
相关论文
共 49 条
  • [31] First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
    Vener, Claudia
    Banzi, Rita
    Ambrogi, Federico
    Ferrero, Annalisa
    Saglio, Giuseppe
    Pravettoni, Gabriella
    Sant, Milena
    BLOOD ADVANCES, 2020, 4 (12) : 2723 - 2735
  • [32] Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
    Hirt, Carsten
    Iannazzo, Sergio
    Chiroli, Silvia
    McGarry, Lisa J.
    le Coutre, Philipp
    Stenke, Leif
    Dahlen, Torsten
    Lipton, Jeffrey H.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (04) : 555 - 567
  • [33] Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
    Carsten Hirt
    Sergio Iannazzo
    Silvia Chiroli
    Lisa J. McGarry
    Philipp le Coutre
    Leif Stenke
    Torsten Dahlén
    Jeffrey H. Lipton
    Applied Health Economics and Health Policy, 2019, 17 : 555 - 567
  • [34] Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
    Ferretti, G.
    Bria, E.
    Giannarelli, D.
    Felici, A.
    Papaldo, P.
    Fabi, A.
    Di Cosimo, S.
    Ruggeri, E. M.
    Milella, M.
    Ciccarese, M.
    Cecere, F. L.
    Gelibter, A.
    Nuzzo, C.
    Cognetti, F.
    Terzoli, E.
    Carlini, P.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1789 - 1796
  • [35] Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
    G Ferretti
    E Bria
    D Giannarelli
    A Felici
    P Papaldo
    A Fabi
    S Di Cosimo
    E M Ruggeri
    M Milella
    M Ciccarese
    F L Cecere
    A Gelibter
    C Nuzzo
    F Cognetti
    E Terzoli
    P Carlini
    British Journal of Cancer, 2006, 94 : 1789 - 1796
  • [36] Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
    Grossi, Francesco
    Aita, Marianna
    Defferrari, Carlotta
    Rosetti, Francesco
    Brianti, Annalisa
    Fasola, Gianpiero
    Vinante, Orazio
    Pronzato, Paolo
    Pappagallo, Giovanni
    ONCOLOGIST, 2009, 14 (05): : 497 - 510
  • [37] Early picc-line infections in non-neutropenic patients are mainly due to E. coli suggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy
    Volpari, Victoria
    Gallouche, Meghann
    Caspar, Yvan
    Thiebaut-Bertrand, Anne
    Epaulard, Olivier
    Pavese, Patricia
    Landelle, Caroline
    Le Marechal, Marion
    INFECTIOUS DISEASES NOW, 2024, 54 (02):
  • [38] Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations
    Goulart, Bernardo H. L.
    Larkins, Erin
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3905 - +
  • [39] TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC)
    Gross, M.
    Pendergrass, K.
    Leitner, S.
    Leichman, G.
    Pugliese, L.
    Silberman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] FULVESTRANT AS FIRST-LINE TREATMENT FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN AFTER PROGRESSION ON PRIOR ADJUVANT THERAPY WITH THIRD-GENERATION AROMATASE INHIBITORS: A PHASE II TRIAL
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Teragni, C.
    Poggi, G.
    Frascaroli, M.
    Jedrychowska, I.
    Amatu, A.
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 71 - 71
12345